항바이오필름 드레싱 시장 - 규모, 점유율, 성장률, 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of anti-biofilm dressings Market

The global anti-biofilm dressings market was valued at USD 1.02 billion in 2025 and is projected to grow to USD 1.11 billion in 2026, ultimately reaching USD 2.16 billion by 2034, at a robust CAGR of 8.66%. North America held the dominant market share of 62.82% in 2025, owing to the presence of established healthcare infrastructure, advanced wound care technologies, and high awareness of biofilm management among healthcare providers. Anti-biofilm dressings are specialized wound care products designed to disrupt biofilms-microbial communities that hinder wound healing-through the use of antimicrobial agents, chelating agents, surfactants, and enzyme-based technologies.

Market Dynamics

Drivers: The rising prevalence of chronic wounds, including diabetic ulcers, pressure ulcers, arterial ulcers, surgical wounds, and burns, is fueling demand for anti-biofilm dressings. Chronic wounds are highly prone to biofilm formation, which delays healing and increases the risk of infections. For example, diabetic foot ulcers affect approximately 18.6 billion people globally (JAMA, 2023), creating a substantial patient pool requiring advanced wound care. Additionally, innovations in minimally invasive dressings and enzyme-based anti-biofilm technologies are improving wound outcomes and patient recovery.

Restraints: Limited adherence to biofilm prevention protocols in emerging countries restricts market adoption. In these regions, awareness about advanced wound care practices is still low, and healthcare professionals may not fully implement best practices, limiting the use of specialized dressings.

Opportunities: Novel anti-biofilm agents and nanotechnology-based solutions offer significant growth potential. Research into nanomaterials, such as silver and zinc oxide nanoparticles, has shown promising results in biofilm disruption. Enzyme-based dressings, which target the extracellular polymeric substance (EPS) of biofilms, are emerging as highly effective alternatives to traditional silver or iodine-based dressings.

Challenges: High costs of anti-biofilm dressings, including silver, honey, and iodine variants, hinder widespread adoption, especially in emerging regions with limited reimbursement. For instance, the cost per silver dressing in the U.K. ranges from USD 8 to USD 20, making these products less accessible in price-sensitive markets.

Market Trends

Recent trends include increased adoption of enzyme-based dressings, such as DNase, protease, and dispersin B, which enhance antimicrobial penetration and effectiveness. These formulations are effective against antibiotic-resistant strains and are gaining traction due to their specificity and biocompatibility. Clinical studies indicate the combined-enzyme approach is particularly effective in treating Pseudomonas aeruginosa biofilms in burn wounds (American Society for Microbiology, 2023).

Segmentation Analysis

By Molecule: Silver-based dressings dominate due to broad-spectrum antimicrobial activity, faster healing, and improved patient comfort. Honey dressings rank third, benefiting from high biofilm inhibition and membrane disruption rates.

By Wound Type: Chronic wounds hold the largest share due to increasing cases of pressure ulcers, diabetic wounds, and venous ulcers, while acute wounds, such as burns, are growing steadily.

By End-User: Hospitals remain the primary end-user segment due to high inpatient admissions for chronic wound care. Home care settings are expected to grow rapidly as patients increasingly seek cost-effective wound management solutions at home.

Regional Outlook

North America: Valued at USD 0.34 billion in 2025 and projected to reach USD 0.37 billion in 2026, the region is the largest market due to advanced healthcare facilities and a strong patient base.

Europe: The second-largest market, supported by extensive promotional campaigns and strong brand presence among key players.

Asia Pacific: Anticipated to witness the highest CAGR by 2034, driven by rising disposable income, awareness, and research initiatives in countries such as China, India, and Malaysia.

Latin America & Middle East & Africa: Both regions are expected to grow steadily due to increased awareness of chronic wounds and adoption of advanced wound care products.

Competitive Landscape

Key players such as Convatec Inc., Molnlycke AB, Smith+Nephew, Coloplast A/S, Solventum, URGO MEDICAL, INTEGRA LIFESCIENCES, Cardinal Health, and B. Braun SE dominate the market. Strategic initiatives, including product launches, collaborations, and clinical studies, are critical for expanding market share. For example, in March 2025, Convatec showcased advanced anti-biofilm dressings at the European Wound Management Association (EWMA) conference, reinforcing its market presence.

Conclusion

The global anti-biofilm dressings market is set for significant growth, increasing from USD 1.02 billion in 2025 to USD 1.11 billion in 2026 and reaching USD 2.16 billion by 2034 at a CAGR of 8.66%. Market expansion is driven by rising chronic wound prevalence, innovations in anti-biofilm technologies, enzyme-based dressings, and increased home care adoption. While high costs and limited awareness in emerging regions pose challenges, research, nanotechnology, and strategic collaborations by key players are anticipated to further strengthen the market. North America remains the dominant region, whereas Asia Pacific is emerging as the fastest-growing market due to rising awareness, disposable income, and technological advancements in wound care.

Segmentation By Molecule

• Silver
• Iodine
• Honey
• Others

By Wound Type

• Chronic Wounds
• Acute Wounds

By End-user

• Hospitals
• Wound Clinics
• Home Care Settings
• Others

By Geography

• North America (By Molecule, Wound Type, End-user, and Country/Sub-region)
  • U.S.
  • Canada
• Europe (By Molecule, Wound Type, End-user, and Country/Sub-region)
  • U.K.
  • Germany
  • France
  • Spain
  • Italy
  • Russia
  • Rest of Europe
• Asia Pacific (By Molecule, Wound Type, End-user, and Country/Sub-region)
  • Japan
  • China
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Molecule, Wound Type, End-user, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Molecule, Wound Type, End-user, and Country/Sub-region)
  • GCC
  • South Africa
  • Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Key Diseases, Key Countries, 2025/2025
• 4.2. Key Industry Developments - Mergers, Acquisitions, and Partnerships
• 4.3. Detailed Product Offerings: Anti-biofilm Dressings, Key Players

5. Global Anti-biofilm Dressings Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Molecule
  • 5.1.1. Silver
  • 5.1.2. Iodine
  • 5.1.3. Honey
  • 5.1.4. Others
• 5.2. Market Analysis, Insights and Forecast - By Wound Type
  • 5.2.1. Chronic Wounds
  • 5.2.2. Acute Wounds
• 5.3. Market Analysis, Insights and Forecast - By End-user
  • 5.3.1. Hospitals
  • 5.3.2. Wound Clinics
  • 5.3.3. Home Care Settings
  • 5.3.4. Others
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Anti-biofilm Dressings Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Molecule
  • 6.1.1. Silver
  • 6.1.2. Iodine
  • 6.1.3. Honey
  • 6.1.4. Others
• 6.2. Market Analysis, Insights and Forecast - By Wound Type
  • 6.2.1. Chronic Wounds
  • 6.2.2. Acute Wounds
• 6.3. Market Analysis, Insights and Forecast - By End-user
  • 6.3.1. Hospitals
  • 6.3.2. Wound Clinics
  • 6.3.3. Home Care Settings
  • 6.3.4. Others
• 6.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Anti-biofilm Dressings Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Molecule
  • 7.1.1. Silver
  • 7.1.2. Iodine
  • 7.1.3. Honey
  • 7.1.4. Others
• 7.2. Market Analysis, Insights and Forecast - By Wound Type
  • 7.2.1. Chronic Wounds
  • 7.2.2. Acute Wounds
• 7.3. Market Analysis, Insights and Forecast - By End-user
  • 7.3.1. Hospitals
  • 7.3.2. Wound Clinics
  • 7.3.3. Home Care Settings
  • 7.3.4. Others
• 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.4.1. U.K.
  • 7.4.2. Germany
  • 7.4.3. France
  • 7.4.4. Spain
  • 7.4.5. Italy
  • 7.4.6. Russia
  • 7.4.7. Rest of Europe

8. Asia Pacific Anti-biofilm Dressings Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Molecule
  • 8.1.1. Silver
  • 8.1.2. Iodine
  • 8.1.3. Honey
  • 8.1.4. Others
• 8.2. Market Analysis, Insights and Forecast - By Wound Type
  • 8.2.1. Chronic Wounds
  • 8.2.2. Acute Wounds
• 8.3. Market Analysis, Insights and Forecast - By End-user
  • 8.3.1. Hospitals
  • 8.3.2. Wound Clinics
  • 8.3.3. Home Care Settings
  • 8.3.4. Others
• 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.4.1. Japan
  • 8.4.2. China
  • 8.4.3. India
  • 8.4.4. Australia
  • 8.4.5. Southeast Asia
  • 8.4.6. Rest of Asia Pacific

9. Latin America Anti-biofilm Dressings Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Service Type
• 9.2. Market Analysis, Insights and Forecast - By Molecule
  • 9.2.1. Silver
  • 9.2.2. Iodine
  • 9.2.3. Honey
  • 9.2.4. Others
• 9.3. Market Analysis, Insights and Forecast - By Wound Type
  • 9.3.1. Chronic Wounds
  • 9.3.2. Acute Wounds
• 9.4. Market Analysis, Insights and Forecast - By End-user
  • 9.4.1. Hospitals
  • 9.4.2. Wound Clinics
  • 9.4.3. Home Care Settings
  • 9.4.4. Others
  • 9.4.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.4.6. Brazil
  • 9.4.7. Mexico
  • 9.4.8. Rest of Latin America

10. Middle East & Africa Anti-biofilm Dressings Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Molecule
  • 10.1.1. Silver
  • 10.1.2. Iodine
  • 10.1.3. Honey
  • 10.1.4. Others
• 10.2. Market Analysis, Insights and Forecast - By Wound Type
  • 10.2.1. Chronic Wounds
  • 10.2.2. Acute Wounds
• 10.3. Market Analysis, Insights and Forecast - By End-user
  • 10.3.1. Hospitals
  • 10.3.2. Wound Clinics
  • 10.3.3. Home Care Settings
  • 10.3.4. Others
• 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.4.1. GCC
  • 10.4.2. South Africa
  • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Coloplast A/S
    • 11.2.1.1. Overview
    • 11.2.1.2. Products
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Convatec Inc.
    • 11.2.2.1. Overview
    • 11.2.2.2. Products
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Molnlycke AB
    • 11.2.3.1. Overview
    • 11.2.3.2. Products
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Solventum
    • 11.2.4.1. Overview
    • 11.2.4.2. Products
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. URGO MEDICAL
    • 11.2.5.1. Overview
    • 11.2.5.2. Products
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. INTEGRA LIFESCIENCES
    • 11.2.6.1. Overview
    • 11.2.6.2. Products
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Cardinal Health
    • 11.2.7.1. Overview
    • 11.2.7.2. Products
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Medline Industries, LP.
    • 11.2.8.1. Overview
    • 11.2.8.2. Products
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. Smith+Nephew
    • 11.2.9.1. Overview
    • 11.2.9.2. Products
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)
  • 11.2.10. B. Braun SE
    • 11.2.10.1. Overview
    • 11.2.10.2. Products
    • 11.2.10.3. SWOT Analysis
    • 11.2.10.4. Recent Developments
    • 11.2.10.5. Strategies
    • 11.2.10.6. Financials (Based on Availability)